1 / 5

International AIDS Vaccine Initiative Labeeb M. Abboud General Counsel September 11, 2007

Partnerships in Promoting Innovation and Managing Risk Scientific and Financial Innovation in AIDS Vaccines. International AIDS Vaccine Initiative Labeeb M. Abboud General Counsel September 11, 2007. International AIDS Vaccine Initiative. Access & uptake. Research & Development.

kimo
Download Presentation

International AIDS Vaccine Initiative Labeeb M. Abboud General Counsel September 11, 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Partnerships in Promoting Innovation and Managing RiskScientific and Financial Innovation in AIDS Vaccines International AIDS Vaccine Initiative Labeeb M. Abboud General Counsel September 11, 2007

  2. International AIDS Vaccine Initiative Access & uptake Research & Development Clinical trials Production Health & delivery systems Political will & finance • 11 years old • 180 staff, 5 offices (Amsterdam, Delhi, Johannesburg, Nairobi, NY), active in 23 countries • $85 million annual budget • Integrated R&D Program • Emphasis on applied research and product development – targeting gaps and promoting rational vaccine design • Industrial project management • 40+ R&D partnerships • 6 vaccine candidates into clinical trials • Trials in 12 countries • Policy & Advocacy • Country and Regional Programs • Sustained commitment to the developing countries Mission To ensure the development of a safe, effective, accessible, preventive HIV vaccine for use throughout the world

  3. An integrated approach to speed an AIDS vaccine Mechanisms of Innovation: Improve the product development pipeline Address major scientific obstacles Strengthen LDC clinical testing infrastructure Implement expanded R&D program Secure and sustain global commitment Enhance global political and financial support Change policy environment Increase private sector engagement Enhance delivery systems Promote public policy for R&D and access Build support for trials and future demand Increase LDC science capacity Foster research consortia Engage LDC partners Refine the model Ensure efficient R&D, internal and partnership processes Innovative IP arrangements

  4. Future Directions to Advance the Vaccine Field • Screening Test of Concept Trials (STOC) • Early look at efficacy through small scale trials in high-risk volunteers • Prioritizing resources by allowing early failures • Accelerating clinical timelines (3 to 5 years) • Replicating Viral Vectors • Science now indicates that replicating vectors may be necessary for an effective AIDS vaccine • IAVI initiating innovative vectors program to prioritize replicating vectors • Currently liaising with regulatory agencies to ensure risk analysis is commensurate with the impact of HIV • Innovation Fund • Funding highly novel ideas to overcome critical scientific challenges • Small grants to assess proof-of-concept • If successful can roll into IAVI’s product development portfolio

  5. IAVI gratefully acknowledges the support of our donors

More Related